Clinical Trial Update: Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating HX008 in combination with bevacizumab or lenvatinib for advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• HX008
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Taizhou Hanzhong biomedical co. LTD | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN